Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) EBT: 2020-2025

Historic EBT for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $90.2 million.

  • Pharming Group N.V's EBT rose 2096.11% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.5 million, marking a year-over-year increase of 485.85%. This contributed to the annual value of -$8.6 million for FY2024, which is 87.90% down from last year.
  • According to the latest figures from Q3 2025, Pharming Group N.V's EBT is $90.2 million, which was up 2,270.99% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's EBT ranged from a high of $90.2 million in Q3 2025 and a low of -$20.0 million during Q3 2021.
  • For the 3-year period, Pharming Group N.V's EBT averaged around $5.6 million, with its median value being $1.5 million (2023).
  • As far as peak fluctuations go, Pharming Group N.V's EBT surged by 32,990.99% in 2022, and later plummeted by 423.65% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's EBT stood at $12.8 million in 2021, then crashed by 66.91% to $4.2 million in 2022, then crashed by 74.75% to $1.1 million in 2023, then surged by 779.61% to $9.4 million in 2024, then soared by 2,096.11% to $90.2 million in 2025.
  • Its EBT stands at $90.2 million for Q3 2025, versus $3.8 million for Q2 2025 and $9.4 million for Q4 2024.